866-997-4948(US-Canada Toll Free)

EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Metabolic Disorders

No. of Pages : 44 Pages


EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022

Summary

Dyslipidemia is a condition in which one or more blood lipid levels are abnormal. It is an underdiagnosed, undertreated, and highly prevalent disease worldwide. Prevalent cases of dyslipidemia in the nine markets is expected to increase from 443.8 million cases in 2012 to 522.0 million cases in 2022 at the rate of 1.76% per year. Factors that influence prevalence include risk factors, disease management, awareness of disease status, population growth, and changes in diagnosis and treatment guidelines. In 2012, India had the highest number of prevalent dyslipidemia cases in the nine major markets at 192.7 million, followed by China at 84.7 million, and the US at 48.6 million. These three countries will continue to dominate in the number of prevalent cases through 2022, during which they will be expected to contribute to 65.6% of the total 522.0 million prevalent cases of all markets combined. This trend is driven mainly by the large populations as the prevalence rates are relatively low in these countries. EU countries such as Germany, Spain, and the UK had prevalence rates that were two or three times that of the other countries. The sex gap for dyslipidemia prevalent cases in the nine markets is not significantly high in this analysis. However, age-group analysis showed that dyslipidemia is most prevalent in people ages 4069 years. The prevalence of dyslipidemia is also affected by the diagnosis and treatment guidelines followed by each country. An update in the ATP guidelines, ATP-IV, is expected to be released at the end of 2012 or 2013 and may impact the prevalent cases forecast.

Scope

  • The dyslipidemia EpiCast Report provide an overview of the risk factors and global trends of dyslipidemia in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to two emerging marketsIndia and China.
  • It includes a 10-year epidemiological forecast of dyslipidemia prevalence segmented by sex and age (by 5-year age groups beginning at 20 years of age) to 2022.

Reasons to buy

  • Develop business strategies by understanding the historical trends of global dyslipidemia market as well as the risk factors and treatment and diagnosis guidelines that shape the trends. 
  • Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans. 
  • Organize sales and marketing efforts by identifying the age group and gender that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7

3 Epidemiology 8
3.1 Disease Background and Definition 8
3.2 Common Diagnostic Criteria for Dyslipidemia 9
3.2.1 NCEP-ATPIII Guidelines 9
3.2.2 ESC/ EAS Guidelines 10
3.3 Risk Factors and Comorbidities 11
3.3.1 Sedentary Lifestyle, High Caloric and Alcohol Intake are Associated with Dyslipidemia 11
3.3.2 Sex Disparity in Dyslipidemia Treatment is Large, but the Reasons are Unclear 11
3.3.3 Dyslipidemia is a Strong Risk Factor for CVD 11
3.4 Secondary Causes of Dyslipidemia 12
3.5 Global Trends 13
3.5.1 United States 13
3.5.2 Europe 14
3.5.3 Asia 14
3.6 Forecast Methodology 15
3.6.1 Sources Used 17
3.6.2 Forecast Assumptions and Methods 21
3.7 Epidemiology Forecast (2012-2022) 25
3.7.1 Prevalent Cases of Dyslipidemia 25
3.7.2 Age-Specific Prevalent Cases of Dyslipidemia 28
3.7.3 Sex-Specific Prevalent Cases of Dyslipidemia 31
3.8 Discussion 33
3.8.1 Conclusions Regarding Epidemiological Trends 33
3.8.2 Limitations of the Analysis 34
3.8.3 Strengths of the Analysis 34

4 Appendix 35
4.1 Bibliography 35
4.2 About the Authors 41
4.2.1 Epidemiologists 41
4.2.2 Reviewers 41
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 42
4.2.4 Global Head of Healthcare 43
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Contact Us 44
4.6 Disclaimer 44

List of Table


Table 1: NCEP-ATP III Classification of TC, LDL-C, HDL-C, and TG (mg/dL) 10
Table 2: Nine Major Markets, Sources of Prevalent Data Used in the Epidemiology Forecast 16
Table 3: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages

List of Chart


Figure 1: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *